Ifomid M 2/400mg

Ifomid M 2/400 is a brand name for Ifosfamide Mesna Injection, which is a chemotherapy medication used to treat various types of cancer. Here are some key points about the product:

Composition:

Each 2/400 injection of Ifomid M 2/400 contains:

1. Ifosfamide: a chemotherapy agent that belongs to the class of alkylating agents
2. Mesna: a medication that helps to prevent bladder damage caused by ifosfamide

Indications:

Ifomid M 2/400 is indicated for:

1. Treatment of ovarian cancer
2. Treatment of breast cancer
3. Treatment of lymphoma
4. Treatment of soft tissue sarcoma

Mechanism of Action:

Ifosfamide works by:

1. Alkylating DNA, leading to cell death
2. Inhibiting DNA repair, further enhancing its cytotoxic effect

Dosage and Administration:

The recommended dosage of Ifomid M 2/400 is:

• 1.5-2.0 grams/m² body surface area as an intravenous infusion over 30-60 minutes
• Repeat every 3-4 weeks

Side Effects:

Common side effects of Ifomid M 2/400 include:

1. Nausea and vomiting
2. Diarrhea
3. Abdominal pain
4. Fatigue
5. Hair loss
6. Changes in menstrual cycle
7. Decreased white blood cell count (neutropenia)
8. Decreased red blood cell count (anemia)
9. Decreased platelet count (thrombocytopenia)

Serious side effects can include:

1. Severe neutropenia or thrombocytopenia
2. Hepatotoxicity (e.g., liver failure, liver damage)
3. Renal toxicity (e.g., kidney failure, kidney damage)
4. Cardiac toxicity (e.g., cardiac arrhythmias, cardiac failure)
5. Pulmonary toxicity (e.g., respiratory failure, pneumonitis)

Contraindications:

Ifomid M 2/400 is contraindicated in patients with:

1. Known hypersensitivity to ifosfamide or mesna
2. Active liver disease or severe liver dysfunction
3. Severe kidney disease or severe kidney dysfunction
4. Pregnancy or breastfeeding (unless absolutely necessary)

Precautions:

1. Patients with a history of cardiac disease or cardiac arrhythmias should be closely monitored while receiving Ifomid M 2/400.
2. Patients with a history of liver disease or kidney dysfunction should receive dose reduction or close monitoring while receiving Ifomid M 2/400.
3. Patients with a history of blood disorders should be closely monitored for signs of blood dyscrasias.
4. Women of childbearing potential should use effective contraception while receiving Ifomid M 2/400.

Patient Counseling:

• Patients should be counseled on the importance of taking their medication as directed and not missing doses.
• Patients should be instructed to report any signs of infection, such as fever, chills, or sore throat.
• Patients should be advised to report any changes in their appetite, nausea, or vomiting.
• Patients should be informed that they may experience hair loss, fatigue, or changes in their menstrual cycle during treatment.

Storage and Handling:

• Store injections at room temperature between 15°C and 30°C (59°F and 86°F).
• Do not expose to direct sunlight or moisture.
• Use within 24 months of opening.

Please note that the dosage and administration information is based on the recommended dosage and may vary depending on individual patient needs and circumstances.